New factor Xa inhibitor shows promise
Published: 2011-12-02 06:57:00
Updated: 2011-12-02 06:57:00
Green Cross Corp. said Wednesday it has received approval from the U.S. Food and Drug Administration to conduct Phase 1 clinical trial of a novel anti-thrombotic which can be classified orally or parenterally administered.
The company said the approval comes after successful completion of pre...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
